These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 16322321

  • 1. Emerging role of the endothelin axis in ovarian tumor progression.
    Bagnato A, Spinella F, Rosanò L.
    Endocr Relat Cancer; 2005 Dec; 12(4):761-72. PubMed ID: 16322321
    [Abstract] [Full Text] [Related]

  • 2. Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis.
    Bagnato A, Rosanò L.
    Cells Tissues Organs; 2007 Dec; 185(1-3):85-94. PubMed ID: 17587812
    [Abstract] [Full Text] [Related]

  • 3. Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression.
    Rosanò L, Spinella F, Di Castro V, Decandia S, Nicotra MR, Natali PG, Bagnato A.
    Exp Biol Med (Maywood); 2006 Jun; 231(6):1128-31. PubMed ID: 16741062
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.
    Spinella F, Rosanò L, Di Castro V, Nicotra MR, Natali PG, Bagnato A.
    Clin Cancer Res; 2004 Jul 15; 10(14):4670-9. PubMed ID: 15269139
    [Abstract] [Full Text] [Related]

  • 5. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
    Rosanò L, Cianfrocca R, Spinella F, Di Castro V, Nicotra MR, Lucidi A, Ferrandina G, Natali PG, Bagnato A.
    Clin Cancer Res; 2011 Apr 15; 17(8):2350-60. PubMed ID: 21220476
    [Abstract] [Full Text] [Related]

  • 6. The endothelin axis in cancer.
    Bagnato A, Rosanò L.
    Int J Biochem Cell Biol; 2008 Apr 15; 40(8):1443-51. PubMed ID: 18325824
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
    Rosanò L, Spinella F, Salani D, Di Castro V, Venuti A, Nicotra MR, Natali PG, Bagnato A.
    Cancer Res; 2003 May 15; 63(10):2447-53. PubMed ID: 12750265
    [Abstract] [Full Text] [Related]

  • 8. The endothelin axis in urologic tumors: mechanisms of tumor biology and therapeutic implications.
    Herrmann E, Bögemann M, Bierer S, Eltze E, Hertle L, Wülfing C.
    Expert Rev Anticancer Ther; 2006 Jan 15; 6(1):73-81. PubMed ID: 16375646
    [Abstract] [Full Text] [Related]

  • 9. ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation.
    Rosanò L, Di Castro V, Spinella F, Decandia S, Natali PG, Bagnato A.
    Exp Biol Med (Maywood); 2006 Jun 15; 231(6):1132-5. PubMed ID: 16741063
    [Abstract] [Full Text] [Related]

  • 10. The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy.
    Bagnato A, Spinella F, Rosanò L.
    Can J Physiol Pharmacol; 2008 Aug 15; 86(8):473-84. PubMed ID: 18758494
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Antitumor effect of green tea polyphenol epigallocatechin-3-gallate in ovarian carcinoma cells: evidence for the endothelin-1 as a potential target.
    Spinella F, Rosanò L, Decandia S, Di Castro V, Albini A, Elia G, Natali PG, Bagnato A.
    Exp Biol Med (Maywood); 2006 Jun 15; 231(6):1123-7. PubMed ID: 16741061
    [Abstract] [Full Text] [Related]

  • 14. The role of fibroblast growth factors and their receptors in prostate cancer.
    Kwabi-Addo B, Ozen M, Ittmann M.
    Endocr Relat Cancer; 2004 Dec 15; 11(4):709-24. PubMed ID: 15613447
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Endothelin-1 and endothelin-3 promote invasive behavior via hypoxia-inducible factor-1alpha in human melanoma cells.
    Spinella F, Rosanò L, Di Castro V, Decandia S, Nicotra MR, Natali PG, Bagnato A.
    Cancer Res; 2007 Feb 15; 67(4):1725-34. PubMed ID: 17308114
    [Abstract] [Full Text] [Related]

  • 17. Integrin alphavbeta3 mediates upregulation of epidermal growth-factor receptor expression and activity in human ovarian cancer cells.
    Lössner D, Abou-Ajram C, Benge A, Reuning U.
    Int J Biochem Cell Biol; 2008 Feb 15; 40(12):2746-61. PubMed ID: 18577466
    [Abstract] [Full Text] [Related]

  • 18. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA, Wilhelm S, Carter C, Kelley SL.
    Semin Oncol; 2006 Aug 15; 33(4):392-406. PubMed ID: 16890795
    [Abstract] [Full Text] [Related]

  • 19. ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma growth in vitro.
    Salani D, Rosanò L, Di Castro V, Spinella F, Venuti A, Padley RJ, Nicotra MR, Natali PG, Bagnato A.
    Clin Sci (Lond); 2002 Aug 15; 103 Suppl 48():318S-321S. PubMed ID: 12193113
    [Abstract] [Full Text] [Related]

  • 20. Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer.
    Li HZ, Wang Y, Gao Y, Shao J, Zhao XL, Deng WM, Liu YX, Yang J, Yao Z.
    Mol Cancer Res; 2008 Jun 15; 6(6):917-28. PubMed ID: 18567796
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.